# Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

> **NCT04742400** · PHASE2 · UNKNOWN · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 12 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** tolebrutinib 60mg
- **DRUG:** tolebrutinib 120mg

## Key facts

- **NCT ID:** NCT04742400
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-15
- **Primary completion:** 2023-06-15
- **Final completion:** 2025-12-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742400, "Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04742400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*